Reply

We are grateful for the interest shown in our study1 by Dai et  al.2 The authors note that our findings were in contrast to previous studies. However, only one prior study demonstrated a benefit to accelerated infliximab induction in acute severe ulcerative colitis (ASUC), and that too was only in the short-term.3 This benefit was not preserved at 2 years. Sin ce then, multiple studies including ours, which was conducted at 3 centers, have failed to show either a short-term or a long-term benefit of accelerated induction in ASUC.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research